Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autoimmune hepatitis: Current and future therapies.

Hepatology communications·2024

Same author

The delta in management of HDV/HBV coinfection: Lessons from a case.

Clinical liver disease·2024

Same author

Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.

The American journal of gastroenterology·2024

Same author

Could the answer to NAFLD be hidden in diabetic therapy? The impact of T2DM treatment on NAFLD.

Clinical liver disease·2024

Same author

Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.

Clinical liver disease·2023

Same author

Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2023

Search research articles

Related Experiment Video

Updated: Dec 27, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Chronic Viral Hepatitis: Current Management and Future Directions.

Albert Do¹, Nancy S Reau²

¹Section of Digestive Diseases Department of Internal Medicine Yale School of Medicine New Haven CT.

Hepatology Communications

|March 7, 2020

Summary

Viral hepatitis management has advanced, with hepatitis C now curable and hepatitis B treatments improving. Further research is crucial for eliminating viral hepatitis and managing complications.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Related Experiment Videos

Last Updated: Dec 27, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Area of Science:

Hepatology and Viral Immunology
Infectious Diseases and Public Health

Background:

Viral hepatitis management has undergone significant evolution over the past decade.
Hepatitis C virus (HCV) is now a curable disease with direct-acting antiviral therapies.
Shifting HCV burden to younger populations due to intravenous drug use impacts screening.

Purpose of the Study:

To review recent advances in identifying and managing viral hepatitis (HCV, HBV, HDV).
To discuss evolving disease characteristics and affected populations.
To outline future directions in viral hepatitis management and elimination strategies.

Main Methods:

Review of recent literature on viral hepatitis diagnosis and treatment.
Analysis of trends in disease burden and patient demographics.
Discussion of current and emerging therapeutic strategies.

Main Results:

Hepatitis C is largely curable, with accessible direct-acting antivirals.
Hepatitis B virus (HBV) management improved with oral nucleos(t)ide therapies, though cure remains elusive.
Progress is being made in managing hepatitis D infection.

Conclusions:

Recent advances offer potential to significantly reduce viral hepatitis disease burden.
Effective screening, linkage to care, and post-treatment management are key for elimination goals.
Further research is needed for refined cure definitions, biomarkers, and multi-pathway therapies.